Brief: Annovis Bio Provides Data Announcement Update For The Phase Ii/Iii Study Of Buntanetap In Alzheimer’S Disease
20/03/2024 11:31
March 20 (Reuters) - Annovis Bio Inc ANVS.N :
* ANNOVIS BIO PROVIDES DATA ANNOUNCEMENT UPDATE FOR THE
PHASE
II/III STUDY OF BUNTANETAP IN ALZHEIMER’S DISEASE
* ANNOVIS BIO INC: TOPLINE EFFICACY DATA IS EXPECTED IN
APRIL.
Source text for Eikon: ID:nGNX5XYcWL
Further company coverage: ANVS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman